Steffel Jan
Division of Electrophysiology and Cardiac Devices, Department of Cardiology, University Heart Center Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland.
Eur Heart J Suppl. 2020 Sep 15;22(Suppl I):I32-I37. doi: 10.1093/eurheartj/suaa102. eCollection 2020 Sep.
Over the last 10 years since the introduction of non-vitamin K antagonist oral anticoagulants (NOACs) into routine clinical practice our experience with these drugs has increased tremendously, also in the context of patients undergoing electrophysiology procedures. While some open questions remain, the available evidence indicates that for the majority of cases, these interventions can safely be performed on NOACs if study-based standard operating procedures are in place and followed. This review summarizes the most current trial evidence and guidelines on the use of NOACs for patients undergoing cardioversion, atrial fibrillation ablation, and device implantations, based on previous work of the author and others.
自从非维生素K拮抗剂口服抗凝药（NOACs）引入常规临床实践的过去10年里，我们在这些药物方面的经验大幅增加，在接受电生理手术的患者中也是如此。虽然仍存在一些未解决的问题，但现有证据表明，在大多数情况下，如果有基于研究的标准操作程序并严格遵循，这些手术可以在服用NOACs的患者身上安全进行。基于作者和其他人之前的工作，本综述总结了关于NOACs在接受心脏复律、房颤消融和器械植入的患者中使用的最新试验证据和指南。
